
I have been prescribed ZEPOSIA. Important Contact Information	
My healthc	are professional who prescribed ZEPOSIA:
Name:	
Office phone nur	nber:
Institution addre	SS:



Patient Information

If used during pregnancy, ZEPOSIA® (ozanimod) can harm the unborn baby. Potential risks include loss of the unborn baby and birth defects.

- Do not use ZEPOSIA[®] if you are pregnant or breast-feeding, or could become pregnant and are not using effective birth control..
- Before starting treatment with ZEPOSIA®:
 - 1. Your prescriber will explain the potential risks to an unborn baby if you become pregnant while taking ZEPOSIA[®] and will regularly inform you how to minimize the risks.
 - 2. You must use effective birth control while taking ZEPOSIA[®] and for 3 months after you stop taking ZEPOSIA[®].
 - **3.** You must have a negative pregnancy test verified by your prescriber and repeated at suitable intervals.
- If you become pregnant while on treatment, ZEPOSIA® must be stopped. Your doctor will advise you of the harmful effects to the baby associated with ZEPOSIA® treatment and ultrasound exams should be performed.
- You should stop taking ZEPOSIA® 3 months before planning a pregnancy.
- If you stop taking ZEPOSIA[®], tell your doctor right away if your disease symptoms get worse as there is a possibility that the disease may return.
- Tell your doctor right away if you are pregnant or breastfeeding, think you might be pregnant or are planning to have a baby.

Please see the back of this reminder card for your prescriber's contact information. For more information about the effects and side effects of ZEPOSIA®, please refer to the Patient Information Leaflet for ZEPOSIA®.

For more information please contact your doctor or pharmacist and refer to the patient information leaflet. You can report side effects directly to the Israeli Ministry of Health by using the on-line form for reporting adverse events on the Home page of the Ministry of health website: www.health.gov.il or by entering the following link: https://sideeffects.health.gov.il

To obtain a copy of this document please contact Bristol Myers Squibb by phone: 03-5231021 or fax: 03-9226896.

2084-IL-2100042













Patient Information

If used during pregnancy, ZEPOSIA® (ozanimod) can harm the unborn baby. Potential risks include loss of the unborn baby and birth defects.

- Do not use ZEPOSIA® if you are pregnant or breast-feeding, or could become pregnant and are not using effective birth control..
- Before starting treatment with ZEPOSIA®:
 - 1. Your prescriber will explain the potential risks to an unborn baby if you become pregnant while taking ZEPOSIA[®] and will regularly inform you how to minimize the risks.
 - 2. You must use effective birth control while taking ZEPOSIA® and for 3 months after you stop taking ZEPOSIA®.
 - **3.** You must have a negative pregnancy test verified by your prescriber and repeated at suitable intervals.
 - If you become pregnant while on treatment, ZEPOSIA[®] must be stopped. Your doctor will advise you of the harmful effects to the baby associated with ZEPOSIA[®] treatment and ultrasound exams should be performed.
 - You should stop taking ZEPOSIA[®] 3 months before planning a pregnancy.
 - If you stop taking ZEPOSIA[®], tell your doctor right away if your disease symptoms get worse as there is a possibility that the disease may return.
 - Tell your doctor right away if you are pregnant or breastfeeding, think you might be pregnant or are planning to have a baby.

Please see the back of this reminder card for your prescriber's contact information. For more information about the effects and side effects of ZEPOSIA®, please refer to the Patient Information Leaflet for ZEPOSIA®.

For more information please contact your doctor or pharmacist and refer to the patient information leaflet. You can report side effects directly to the Israeli Ministry of Health by using the on-line form for reporting adverse events on the Home page of the Ministry of health website: www.health.gov.il or by entering the following link: https://sideeffects.health.gov.il

To obtain a copy of this document please contact Bristol Myers Squibb by phone: 03-5231021 or fax: 03-9226896.

^{2084-IL-2100042}

